Quick Answer
HALOZYME THERAPEUTICS, INC. reported Total Assets of $2.53 billion for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +22.4% in Total Assets from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $89.51 million | Q3 2011: $78.24 million | Q1 2012: $134.72 million | Q2 2012: $121.75 million | Q3 2012: $107.98 million | Q1 2013: $116.87 million | Q2 2013: $107.39 million | Q3 2013: $110.15 million | Q1 2014: $197.69 million | Q2 2014: $182.05 million | Q3 2014: $164.63 million | Q1 2015: $159.13 million | Q2 2015: $174.05 million | Q3 2015: $158.73 million | Q1 2016: $309.10 million | Q2 2016: $296.13 million | Q3 2016: $282.50 million | Q1 2017: $226.77 million | Q2 2017: $344.79 million | Q3 2017: $357.15 million | Q1 2018: $495.47 million | Q2 2018: $474.75 million | Q3 2018: $444.51 million | Q1 2019: $429.11 million | Q2 2019: $417.83 million | Q3 2019: $370.36 million | Q1 2020: $492.35 million | Q2 2020: $527.00 million | Q3 2020: $524.03 million | Q1 2021: $966.58 million | Q2 2021: $1.03 billion | Q3 2021: $1.19 billion | Q1 2022: $1.16 billion | Q2 2022: $1.78 billion | Q3 2022: $1.86 billion | Q1 2023: $1.70 billion | Q2 2023: $1.81 billion | Q3 2023: $1.89 billion | Q1 2024: $1.84 billion | Q2 2024: $1.97 billion | Q3 2024: $2.12 billion | Q1 2025: $2.20 billion | Q2 2025: $2.05 billion | Q3 2025: $2.22 billion.
- Over the full 16 years of available data (2010 to 2025), HALOZYME THERAPEUTICS, INC.'s Total Assets has grown by 2,664.6%.
- Historical annual values: Fiscal year 2025: $2.53 billion | Fiscal year 2024: $2.06 billion | Fiscal year 2023: $1.73 billion | Fiscal year 2022: $1.84 billion | Fiscal year 2021: $1.10 billion | Fiscal year 2020: $579.92 million | Fiscal year 2019: $565.87 million | Fiscal year 2018: $440.25 million | Fiscal year 2017: $519.95 million | Fiscal year 2016: $261.52 million | Fiscal year 2015: $181.79 million | Fiscal year 2014: $165.98 million | Fiscal year 2013: $101.79 million | Fiscal year 2012: $134.73 million | Fiscal year 2011: $65.76 million | Fiscal year 2010: $91.35 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: